(Q37076172)

18 August 2017

1 reference

title

Targeting the epidermal growth factor receptor in high-grade astrocytomas (English)

1 reference

18 August 2017

Will R Voelzke

1

1 reference

18 August 2017

W Jeffery Petty

series ordinal

2

1 reference

18 August 2017

Glenn J Lesser

series ordinal

3

1 reference

18 August 2017

publication date

5 February 2008

1 reference

Current Treatment Options in Oncology

18 August 2017

published in

1 reference

18 August 2017

volume

9

1 reference

18 August 2017

issue

1

1 reference

18 August 2017

page(s)

23-31

1 reference

EGFR tyrosine kinase domain mutations in human gliomas

18 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11864-008-0053-5

In vitro responsiveness of glioma cell lines to multimodality treatment with radiotherapy, temozolomide, and epidermal growth factor receptor inhibition with cetuximab

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11864-008-0053-5

Time and dose-dependent radiosensitization of the glioblastoma multiforme U251 cells by the EGF receptor tyrosine kinase inhibitor ZD1839 ('Iressa').

21 January 2018

1 reference

https://pubmed.ncbi.nlm.nih.gov/18247132

12 December 2020

Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting

1 reference

https://pubmed.ncbi.nlm.nih.gov/18247132

12 December 2020

Activity of anti-epidermal growth factor receptor monoclonal antibody C225 against glioblastoma multiforme.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18247132

12 December 2020

The EGF receptor family as targets for cancer therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/18247132

12 December 2020

Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme

1 reference

https://pubmed.ncbi.nlm.nih.gov/18247132

12 December 2020

Cyclin degradation for cancer therapy and chemoprevention

1 reference

https://pubmed.ncbi.nlm.nih.gov/18247132

12 December 2020

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18247132

12 December 2020

Bexarotene and erlotinib for aerodigestive tract cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/18247132

12 December 2020

Antiproliferative, antiangiogenic and proapoptotic activity of h-R3: A humanized anti-EGFR antibody

1 reference

https://pubmed.ncbi.nlm.nih.gov/18247132

12 December 2020

Phase II trial of gefitinib in recurrent glioblastoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/18247132

12 December 2020

Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma

1 reference

https://pubmed.ncbi.nlm.nih.gov/18247132

12 December 2020

Treatment of recurrent malignant gliomas with high-dose 13-cis-retinoic acid.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18247132

12 December 2020

Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa).

1 reference

https://pubmed.ncbi.nlm.nih.gov/18247132

12 December 2020

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/18247132

12 December 2020

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://pubmed.ncbi.nlm.nih.gov/18247132

12 December 2020

Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: report from a phase I/II trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18247132

12 December 2020

Treatment of primary glioblastoma multiforme with cetuximab, radiotherapy and temozolomide (GERT)--phase I/II trial: study protocol

1 reference

https://pubmed.ncbi.nlm.nih.gov/18247132

12 December 2020

Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/18247132

12 December 2020

Therapeutic anti-EGFR antibody 806 generates responses in murine de novo EGFR mutant-dependent lung carcinomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/18247132

12 December 2020

Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel

1 reference

https://pubmed.ncbi.nlm.nih.gov/18247132

12 December 2020

Anti-epidermal growth factor receptor monoclonal antibody cetuximab augments radiation effects in glioblastoma multiforme in vitro and in vivo

1 reference

https://pubmed.ncbi.nlm.nih.gov/18247132

12 December 2020

Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase

1 reference

https://pubmed.ncbi.nlm.nih.gov/18247132

12 December 2020

Prognostic and pathologic significance of quantitative protein expression profiling in human gliomas.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18247132

12 December 2020

MGMT gene silencing and benefit from temozolomide in glioblastoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/18247132

12 December 2020

Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18247132

12 December 2020

Combinatorial efficacy achieved through two-point blockade within a signaling pathway-a chemical genetic approach.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18247132

12 December 2020

A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors

1 reference

https://pubmed.ncbi.nlm.nih.gov/18247132

12 December 2020

A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma

1 reference

https://pubmed.ncbi.nlm.nih.gov/18247132

12 December 2020

Therapeutic options for recurrent high-grade glioma in adult patients: recent advances

1 reference

https://pubmed.ncbi.nlm.nih.gov/18247132

12 December 2020

Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18247132

12 December 2020

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/18247132

12 December 2020

Cancer statistics, 2007

1 reference

https://pubmed.ncbi.nlm.nih.gov/18247132

12 December 2020

10.1007/S11864-008-0053-5

Identifiers

DOI

1 reference

18 August 2017

1 reference